{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T21:59:29Z","timestamp":1794866369063,"version":"4.9.1"},"reference-count":108,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2002,10,1]]},"abstract":"<jats:p>A World Health Organization (WHO) classification of hematopoietic and lymphoid neoplasms has recently been published. This classification was developed through the collaborative efforts of the Society for Hematopathology, the European Association of Hematopathologists, and more than 100 clinical hematologists and scientists who are internationally recognized for their expertise in hematopoietic neoplasms. For the lymphoid neoplasms, this classification provides a refinement of the entities described in the Revised European-American Lymphoma (REAL) Classification\u2014a system that is now used worldwide. To date, however, there has been no published explanation or rationale given for the WHO classification of the myeloid neoplasms. The purpose of this communication is to outline briefly the WHO classification of malignant myeloid diseases, to draw attention to major differences between it and antecedent classification schemes, and to provide the rationale for those differences.<\/jats:p>","DOI":"10.1182\/blood-2002-04-1199","type":"journal-article","created":{"date-parts":[[2002,9,18]],"date-time":"2002-09-18T12:26:06Z","timestamp":1032351966000},"page":"2292-2302","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1705,"title":["The World Health Organization (WHO) classification of the myeloid neoplasms"],"prefix":"10.1182","volume":"100","author":[{"given":"James W.","family":"Vardiman","sequence":"first","affiliation":[{"name":"From the Department of Pathology, University of Chicago, IL; Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston; and Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy Lee","family":"Harris","sequence":"additional","affiliation":[{"name":"From the Department of Pathology, University of Chicago, IL; Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston; and Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard D.","family":"Brunning","sequence":"additional","affiliation":[{"name":"From the Department of Pathology, University of Chicago, IL; Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston; and Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111822242415100_B1","volume-title":"World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues.","author":"Jaffe","year":"2001"},{"key":"2019111822242415100_B2","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1200\/JCO.1999.17.12.3835","article-title":"World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting\u2014Airlie House, Virginia, November 1997.","volume":"17","author":"Harris","year":"1999","journal-title":"J Clin Oncol."},{"key":"2019111822242415100_B3","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group.","volume":"84","author":"Harris","year":"1994","journal-title":"Blood."},{"key":"2019111822242415100_B4","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2141.1976.tb03563.x","article-title":"Proposals for the classification of the acute leukaemias: French-American-British Cooperative Group.","volume":"33","author":"Bennett","year":"1976","journal-title":"Br J Haematol."},{"key":"2019111822242415100_B5","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2141.1982.tb08475.x","article-title":"The French-American-British (FAB) Co-operative Group. Proposals for the classification of the myelodysplastic syndromes.","volume":"51","author":"Bennett","year":"1982","journal-title":"Br J Haematol."},{"key":"2019111822242415100_B6","first-page":"339","article-title":"Diagnosis and classification of the polycythemias.","volume":"12","author":"Berlin","year":"1975","journal-title":"Semin Hematol."},{"key":"2019111822242415100_B7","first-page":"29","article-title":"Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival and leukemia transition by treatment.","volume":"34","author":"Murphy","year":"1997","journal-title":"Semin Hematol."},{"key":"2019111822242415100_B8","first-page":"1287","article-title":"A new morphologic classification system for acute promyelocytic leukemia distinguishes cases with underlying PLZF\/RARA gene rearrangements.","volume":"96","author":"Sainty","year":"2000","journal-title":"Blood."},{"key":"2019111822242415100_B9","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.1365-2141.1990.tb06365.x","article-title":"Prognostic importance of immunophenotyping in adults with acute myelocytic leukaemia: the significance of the stem-cell glycoprotein CD34 (My10).","volume":"76","author":"Geller","year":"1990","journal-title":"Br J Haematol."},{"key":"2019111822242415100_B10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/1097-0320(20010215)46:1<23::AID-CYTO1033>3.0.CO;2-Z","article-title":"Optimal number of reagents required to evaluate hematolymphoid neoplasias: results of an international consensus meeting.","volume":"46","author":"Braylan","year":"2001","journal-title":"Cytometry."},{"key":"2019111822242415100_B11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2257.2002.00135.x","article-title":"Revised guideline on immunophenotyping in acute leukemias and chronic lymphoproliferative disorders.","volume":"24","author":"Bain","year":"2002","journal-title":"Clin Lab Haematol."},{"key":"2019111822242415100_B12","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1309\/K2PH-L2U7-722B-B1YR","article-title":"Realistic pathologic classification of acute myeloid leukemias.","volume":"115","author":"Arber","year":"2001","journal-title":"Am J Clin Pathol."},{"key":"2019111822242415100_B13","first-page":"1826","article-title":"Revised classification of acute myeloid leukemia.","volume":"10","author":"Head","year":"1996","journal-title":"Leukemia."},{"key":"2019111822242415100_B14","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1182\/blood.V89.9.3323","article-title":"Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkable distinct responses to standard chemotherapy. A Southwest Oncology Group study.","volume":"89","author":"Leith","year":"1997","journal-title":"Blood."},{"key":"2019111822242415100_B15","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1056\/NEJM199710093371501","article-title":"All-trans-retinoid acid in acute promyelocytic leukemia.","volume":"337","author":"Tallman","year":"1997","journal-title":"N Engl J Med."},{"key":"2019111822242415100_B16","doi-asserted-by":"crossref","first-page":"3767","DOI":"10.1200\/JCO.1999.17.12.3767","article-title":"Patients with the t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered.","volume":"17","author":"Byrd","year":"1999","journal-title":"J Clin Oncol."},{"key":"2019111822242415100_B17","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00001622-200201000-00004","article-title":"Proposed changes in the definitions of acute myeloid leukemia and myelodysplastic syndrome: are they helpful?","volume":"14","author":"Head","year":"2002","journal-title":"Curr Opin Oncol."},{"key":"2019111822242415100_B18","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.1182\/blood.V96.12.3932","article-title":"The role of apoptosis, proliferation and the Bcl-2-related proteins in myelodysplastic syndromes and acute myeloid leukemias secondary to MDS.","volume":"96","author":"Parker","year":"2000","journal-title":"Blood."},{"key":"2019111822242415100_B19","first-page":"963","article-title":"High expression of the multidrug resistance P-glycoprotein in high-risk myelodysplasia is associated with immature phenotype.","volume":"7","author":"Sonneveld","year":"1993","journal-title":"Leukemia."},{"key":"2019111822242415100_B20","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3109\/10428199309064263","article-title":"Treatment of myelodysplastic syndromes with AML-type chemotherapy.","volume":"11(suppl 2)","author":"Estey","year":"1993","journal-title":"Leuk Lymphoma."},{"key":"2019111822242415100_B21","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1182\/blood.V90.8.2969","article-title":"Effects of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy.","volume":"90","author":"Estey","year":"1997","journal-title":"Blood."},{"key":"2019111822242415100_B22","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1200\/JCO.1996.14.9.2486","article-title":"Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndromes as defined by French-American-British criteria: a Cancer and Leukemia Group B study.","volume":"14","author":"Bernstein","year":"1996","journal-title":"J Clin Oncol."},{"key":"2019111822242415100_B23","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes.","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood."},{"key":"2019111822242415100_B24","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1182\/blood.V92.7.2322","article-title":"The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial.","volume":"92","author":"Grimwade","year":"1998","journal-title":"Blood."},{"key":"2019111822242415100_B25","first-page":"261","article-title":"Prognostic value of cytogenetic findings in adults with acute myeloid leukemia.","volume":"72","author":"Mrozek","year":"2000","journal-title":"Int J Hematol."},{"key":"2019111822242415100_B26","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1182\/blood.V96.13.4075","article-title":"Karyotypic analysis predicts outcome of pre-remission and post-remission therapy in adult acute myeloid leukemia: a Southwest Oncology Group\/Eastern Cooperative Oncology Group study.","volume":"96","author":"Slovak","year":"2000","journal-title":"Blood."},{"key":"2019111822242415100_B27","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1182\/blood.V99.6.1909","article-title":"Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia.","volume":"99","author":"Pedersen-Bjergaard","year":"2002","journal-title":"Blood."},{"key":"2019111822242415100_B28","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/gcc.10040","article-title":"International workshop on the relationship of prior therapy to balanced chromosome aberrations in therapy-related leukemia and myelodysplastic syndromes and acute leukemia: overview report.","volume":"33","author":"Rowley","year":"2002","journal-title":"Genes Chromosomes Cancer."},{"key":"2019111822242415100_B29","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.1182\/blood.V85.12.3695.bloodjournal85123695","article-title":"Heterogeneity in CBF \u03b2\/MYH11 fusion messages encoded by the inv(16)(p13q22) and the t(16;16)(p13;q22) in acute myelogenous leukemia.","volume":"85","author":"Shurtleff","year":"1995","journal-title":"Blood."},{"key":"2019111822242415100_B30","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1200\/JCO.2001.19.9.2482","article-title":"Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B Study.","volume":"19","author":"Mrozek","year":"2001","journal-title":"J Clin Oncol."},{"key":"2019111822242415100_B31","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/sj.leu.2400629","article-title":"Detection of CBF\u03b2\/MYH11 fusion transcripts in acute myeloid leukemia: heterogeneity of cytological and molecular characteristics.","volume":"11","author":"Costello","year":"1997","journal-title":"Leukemia."},{"key":"2019111822242415100_B32","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1365-2141.1987.tb01325.x","article-title":"Clinical and laboratory features of de novo acute myeloid leukaemia with trilineage myelodysplasia.","volume":"66","author":"Brito-Babapulle","year":"1987","journal-title":"Br J Haematol."},{"key":"2019111822242415100_B33","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1365-2141.1987.tb01328.x","article-title":"Dysmegakaryocytopoiesis in acute leukaemias: its predominance in myelomonocytic (M4) leukaemia and implication for poor response to chemotherapy.","volume":"66","author":"Jinnai","year":"1987","journal-title":"Br J Haematol."},{"key":"2019111822242415100_B34","first-page":"520","article-title":"Evaluation of the dysmyelopoiesis in 336 patients with de novo acute myeloid leukemia: major importance of dysgranulopoiesis for remission and survival.","volume":"6","author":"Goasguen","year":"1992","journal-title":"Leukemia."},{"key":"2019111822242415100_B35","first-page":"946","article-title":"De novo AML with dysplastic hematopoiesis: cytogenetic and prognostic significance.","volume":"10","author":"Gahn","year":"1996","journal-title":"Leukemia."},{"key":"2019111822242415100_B36","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1182\/blood.V65.6.1364.bloodjournal6561364","article-title":"Therapy-related acute myeloid leukemia and myelodysplastic syndrome: a clinical and morphologic study of 65 cases.","volume":"65","author":"Michels","year":"1985","journal-title":"Blood."},{"key":"2019111822242415100_B37","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1200\/JCO.1986.4.3.325","article-title":"Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7.","volume":"4","author":"Le Beau","year":"1986","journal-title":"J Clin Oncol."},{"key":"2019111822242415100_B38","first-page":"1303","article-title":"Myeloid leukemia after hematotoxins.","volume":"104(suppl 6)","author":"Larson","year":"1996","journal-title":"Environ Health Perspect."},{"key":"2019111822242415100_B39","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0272-2712(18)30077-5","article-title":"Therapy-related acute leukemia.","volume":"20","author":"Karp","year":"2000","journal-title":"Clin Lab Med."},{"key":"2019111822242415100_B40","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/gcc.1115","article-title":"Duplication or amplification of chromosome band 11q23, including the unrearranged MLL gene, is a recurrent abnormality in therapy-related MDS and AML, and is closely related to mutation of the TP53 gene and to previous therapy with alkylating agents.","volume":"31","author":"Andersen","year":"2001","journal-title":"Genes Chromosomes Cancer."},{"key":"2019111822242415100_B41","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1182\/blood.V70.5.1412.1412","article-title":"Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung.","volume":"70","author":"Ratain","year":"1987","journal-title":"Blood."},{"key":"2019111822242415100_B42","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1182\/blood.V79.7.1892.1892","article-title":"Balanced translocations involving chromosome bands 11q23 and 21q22 in therapy-related leukemia.","volume":"79","author":"Larson","year":"1982","journal-title":"Blood."},{"key":"2019111822242415100_B43","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1182\/blood.V78.4.1147.1147","article-title":"Balanced translocations involving chromosome bands 11q23 and 21q22 are highly characteristic of myelodysplasia and leukemia following therapy with cytostatic agents targeting at DNA-topoisomerase II.","volume":"78","author":"Pedersen-Bjergaard","year":"1991","journal-title":"Blood."},{"key":"2019111822242415100_B44","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1056\/NEJM199112123252402","article-title":"Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia.","volume":"325","author":"Pui","year":"1991","journal-title":"N Engl J Med."},{"key":"2019111822242415100_B45","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/sj.leu.2401021","article-title":"Secondary acute leukemia and myelodysplastic syndrome with 11q23 abnormalities. EU Concerted Action 11q23 Workshop.","volume":"12","author":"Secker-Walker","year":"1998","journal-title":"Leukemia."},{"key":"2019111822242415100_B46","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/gcc.10046","article-title":"11q23 balanced chromosome aberrations in treatment-related myelodysplastic syndromes and acute leukemia: report from an international workshop.","volume":"33","author":"Bloomfield","year":"2002","journal-title":"Genes Chromosomes Cancer."},{"key":"2019111822242415100_B47","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/j.1365-2141.1995.tb05208.x","article-title":"Minimally differentiated erythroleukaemia (AML M6 \u2018variant\u2019): a rare subset of AML distinct from AML M6.","volume":"90","author":"Garand","year":"1995","journal-title":"Br J Haematol."},{"key":"2019111822242415100_B48","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/1096-8652(200009)65:1<5::AID-AJH2>3.0.CO;2-U","article-title":"Diagnosis and characterization of acute erythroleukemia subsets by determining the percentages of myeloblasts and proerythroblasts in 69 cases.","volume":"65","author":"Kowal-Vern","year":"2000","journal-title":"Am J Hematol."},{"key":"2019111822242415100_B49","doi-asserted-by":"crossref","first-page":"761","DOI":"10.2169\/internalmedicine.39.761","article-title":"Minimally differentiated erythroleukemia: recognition of erythroid precursors and progenitors.","volume":"39","author":"Shichishima","year":"2000","journal-title":"Intern Med."},{"key":"2019111822242415100_B50","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1136\/jcp.54.3.205","article-title":"Acute erythremic myelosis (true erythroleukaemia): a variant of AML FAB-M6.","volume":"54","author":"Hasserjian","year":"2001","journal-title":"J Clin Pathol."},{"key":"2019111822242415100_B51","doi-asserted-by":"crossref","first-page":"843","DOI":"10.2169\/internalmedicine.39.843","article-title":"Sialyl-Tn- and neuron-specific enolase-positive minimally differentiated erythroleukemia.","volume":"39","author":"Muroi","year":"2000","journal-title":"Intern Med."},{"key":"2019111822242415100_B52","volume-title":"La Malattie Eritremiche ed Eritroleucemiche.","author":"DiGuglielmo","year":"1962"},{"key":"2019111822242415100_B53","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1365-2141.1981.tb07191.x","article-title":"Acute myelodysplasia with myelofibrosis: a report of eight cases.","volume":"49","author":"Sultan","year":"1981","journal-title":"Br J Haematol."},{"key":"2019111822242415100_B54","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0145-2126(92)90100-L","article-title":"Myelodysplastic syndromes (MDS) and acute myeloid leukemias (AML) with myelofibrosis.","volume":"16","author":"Imbert","year":"1992","journal-title":"Leuk Res."},{"key":"2019111822242415100_B55","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/ajcp\/67.4.334","article-title":"Acute myelofibrosis: a report of three cases.","volume":"67","author":"Fabich","year":"1977","journal-title":"Am J Clin Pathol."},{"key":"2019111822242415100_B56","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/1097-0142(197901)43:1<279::AID-CNCR2820430141>3.0.CO;2-L","article-title":"Acute (\u201cmalignant\u201d) myelosclerosis.","volume":"43","author":"Bearman","year":"1979","journal-title":"Cancer."},{"key":"2019111822242415100_B57","first-page":"472","article-title":"Malignant myelosclerosis.","volume":"ii","author":"Lewis","year":"1963","journal-title":"Br Med J."},{"key":"2019111822242415100_B58","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1365-2141.1979.tb03693.x","article-title":"Megakaryoblastic leukaemia (acute myelofibrosis): a report of three cases.","volume":"42","author":"Den Ottolander","year":"1979","journal-title":"Br J Haematol"},{"key":"2019111822242415100_B59","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/ajcp\/88.5.578","article-title":"Acute myelofibrosis: immunohistochemical study of four cases and comparison with acute megakaryoblastic leukemia.","volume":"88","author":"Hruban","year":"1987","journal-title":"Am J Clin Pathol."},{"key":"2019111822242415100_B60","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/1097-0142(19830701)52:1<83::AID-CNCR2820520117>3.0.CO;2-9","article-title":"Dysmyelopoietic syndromes: a search for prognostic factors in 193 patients.","volume":"52","author":"Coiffier","year":"1983","journal-title":"Cancer."},{"key":"2019111822242415100_B61","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1365-2141.1985.tb04063.x","article-title":"A study of 101 cases according to the FAB classification.","volume":"61","author":"Vallespi","year":"1985","journal-title":"Br J Haematol."},{"key":"2019111822242415100_B62","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1365-2141.1987.tb06138.x","article-title":"Utility of the FAB classification for myelodysplastic syndromes: investigation of prognostic factors in 237 cases.","volume":"65","author":"Kerkhofs","year":"1987","journal-title":"Br J Haematol."},{"key":"2019111822242415100_B63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0165-4608(88)90303-2","article-title":"Recommendations for a morphologic, immunologic and cytogenetic (MIC) working classification of the primary and therapy related myelodysplastic disorders.","volume":"32","author":"Third MIC Cooperative Study Group","year":"1988","journal-title":"Cancer Genet Cytogenet."},{"key":"2019111822242415100_B64","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1365-2141.1990.tb02536.x","article-title":"Two types of acquired idiopathic sideroblastic anaemia (AISA).","volume":"74","author":"Gattermann","year":"1990","journal-title":"Br J Haematol."},{"key":"2019111822242415100_B65","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1046\/j.1365-2141.2000.01940.x","article-title":"Two types of acquired idiopathic sideroblastic anaemia (AISA): a time-tested distinction.","volume":"108","author":"Germing","year":"2000","journal-title":"B J Haematol."},{"key":"2019111822242415100_B66","first-page":"67","article-title":"Unclassifiable myelodysplastic syndrome: a study of sixteen cases with a proposal for a new subtype [abstract].","volume":"62","author":"Michels","year":"1990","journal-title":"Lab Invest."},{"key":"2019111822242415100_B67","first-page":"20","article-title":"Refractory cytopenia with multilineage dysplasia: further characterization of an \u201cunclassifiable\u201d myelodysplastic syndrome.","volume":"10","author":"Rosati","year":"1996","journal-title":"Leukemia."},{"key":"2019111822242415100_B68","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1038\/sj.leu.2401165","article-title":"Multilineage dysplasia without increased blasts identifies a poor prognosis subset of myelodysplastic syndromes [letter].","volume":"12","author":"Balduini","year":"1998","journal-title":"Leukemia."},{"key":"2019111822242415100_B69","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0145-2126(00)00088-6","article-title":"Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients.","volume":"24","author":"Germing","year":"2000","journal-title":"Leuk Res."},{"key":"2019111822242415100_B70","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1182\/blood.V98.10.2935","article-title":"Myelodysplastic syndromes, from French-American-British to World Health Organization: comparison of classifications on 431 unselected patients from a single institution.","volume":"98","author":"Nosslinger","year":"2001","journal-title":"Blood."},{"key":"2019111822242415100_B71","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1006\/geno.2000.6414","article-title":"Transcript map and comparative analysis of the 1.5-Mb commonly deleted segment of human 5q31 in malignant myeloid diseases with a del(5q).","volume":"71","author":"Lai","year":"2001","journal-title":"Genomics."},{"key":"2019111822242415100_B72","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s004390051020","article-title":"Physical mapping of the human ATX1 homologue (HAH1) to the critical region of the 5q\u2212 syndrome within 5q32, and immediately adjacent to the SPARC gene.","volume":"106","author":"Boultwood","year":"2000","journal-title":"Hum Genet."},{"key":"2019111822242415100_B73","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/251437a0","article-title":"Distinct haematological disorder with deletion of the long arm of no. 5 chromosome.","volume":"251","author":"Van den Berghe","year":"1974","journal-title":"Nature."},{"key":"2019111822242415100_B74","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1182\/blood.V84.10.3253.3253","article-title":"The 5q\u2212 syndrome.","volume":"84","author":"Boultwood","year":"1994","journal-title":"Blood."},{"key":"2019111822242415100_B75","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1365-2141.1994.tb06734.x","article-title":"The chronic myeloid leukemias: guidelines for distinguishing the chronic granulocytic, atypical chronic myeloid and chronic myelomonocytic leukaemias.","volume":"87","author":"Bennett","year":"1994","journal-title":"Br J Haematol."},{"key":"2019111822242415100_B76","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3109\/10428199309148501","article-title":"Chronic myelomonocytic leukaemia (CMML): a myelodysplastic or myeloproliferative syndrome?","volume":"9","author":"Michaux","year":"1993","journal-title":"Leuk Lymphoma."},{"key":"2019111822242415100_B77","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0165-4608(91)90235-M","article-title":"Chronic myelomonocytic leukemia: single entity or heterogeneous disorder? A prospective multicenter study of 100 patients.","volume":"55","author":"Groupe Francais de Cytogenetique Hematologique","year":"1991","journal-title":"Cancer Genet Cytogenet."},{"key":"2019111822242415100_B78","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0145-2126(97)00192-6","article-title":"Problems in the classification of CMML\u2014dysplastic versus proliferative type.","volume":"22","author":"Germing","year":"1998","journal-title":"Leuk Res."},{"key":"2019111822242415100_B79","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood.V99.3.840","article-title":"Prognostic factors in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients.","volume":"99","author":"Onida","year":"2002","journal-title":"Blood."},{"key":"2019111822242415100_B80","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2141.1987.tb06142.x","article-title":"Chronic and subacute myelomonocytic leukemia in the adult: a report of 60 cases with special reference to prognostic factors.","volume":"65","author":"Fenaux","year":"1987","journal-title":"Br J Haematol."},{"key":"2019111822242415100_B81","first-page":"766","article-title":"Chronic myelomonocytic leukemia.","volume":"4","author":"Stornilio","year":"1989","journal-title":"Leukemia."},{"key":"2019111822242415100_B82","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/S0025-6196(12)61287-7","article-title":"Chronic myelomonocytic leukemia: natural history and prognostic determinants.","volume":"64","author":"Tefferi","year":"1989","journal-title":"Mayo Clin Proc."},{"key":"2019111822242415100_B83","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/S0950-3536(87)80031-8","article-title":"Haematological classification of the chronic myeloid leukaemias.","volume":"1","author":"Shepherd","year":"1987","journal-title":"Baillieres Clin Haematol."},{"key":"2019111822242415100_B84","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1023\/A:1008393002748","article-title":"Clinical, hematological and cytogenetic characteristics of atypical chronic myeloid leukemia.","volume":"11","author":"Hernandez","year":"2000","journal-title":"Ann Oncol."},{"key":"2019111822242415100_B85","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1182\/blood.V91.1.365","article-title":"Differentiating juvenile myelomoncytic leukemia from infectious disease.","volume":"91","author":"Niemeyer","year":"1998","journal-title":"Blood."},{"key":"2019111822242415100_B86","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/sj.leu.2401342","article-title":"Myelodysplastic syndrome, juvenile myelomonocytic leukemia, and acute myeloid leukemia associated with complete or partial monsomy 7. European Working Group on MDS in Childhood (EWOG-MDS).","volume":"13","author":"Hasle","year":"1999","journal-title":"Leukemia."},{"key":"2019111822242415100_B87","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1172\/JCI9083","article-title":"Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia.","volume":"105","author":"Druker","year":"2000","journal-title":"J Clin Invest."},{"key":"2019111822242415100_B88","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1600-0609.1996.tb01379.x","article-title":"An assessment of the clinico-hematological criteria for the accelerated phase of chronic myeloid leukemia.","volume":"57","author":"Cervantes","year":"1996","journal-title":"Eur J Haematol."},{"key":"2019111822242415100_B89","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1046\/j.1365-2141.1997.3453159.x","article-title":"Bone marrow transplantation for chronic myeloid leukaemia: the effects of differing criteria for defining chronic phase on probabilities of survival and relapse.","volume":"99","author":"Savage","year":"1997","journal-title":"Br J Haematol."},{"key":"2019111822242415100_B90","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1182\/blood.V82.3.691.691","article-title":"Chronic myelogenous leukemia: a concise update.","volume":"82","author":"Kantarjian","year":"1993","journal-title":"Blood."},{"key":"2019111822242415100_B91","volume-title":"Tumors of the Bone Marrow.","author":"Brunning","year":"1994"},{"key":"2019111822242415100_B92","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0002-9343(96)00061-7","article-title":"Chronic myelogenous leukemia: a review.","volume":"100","author":"Cortes","year":"1996","journal-title":"Am J Med."},{"key":"2019111822242415100_B93","first-page":"693","article-title":"Coexistence d'un myelome et une leucemie granuleuse en absence de tout traitement: etude de quatre observations [Coexistence of a myeloma and a granulocytic leukemia in the absence of any treatment: study of 4 cases].","volume":"14","author":"Tursz","year":"1974","journal-title":"Nouv Rev Fr Hematol."},{"key":"2019111822242415100_B94","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/1097-0142(19900701)66:1<162::AID-CNCR2820660129>3.0.CO;2-Z","article-title":"Chronic neutrophilic leukemia and multiple myeloma: an association with \u03bb light chain expression.","volume":"66","author":"Standen","year":"1990","journal-title":"Cancer."},{"key":"2019111822242415100_B95","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1159\/000204241","article-title":"Coexistence of chronic neutrophilic leukemia with light chain myeloma.","volume":"91","author":"Cehreli","year":"1994","journal-title":"Acta Haematol."},{"key":"2019111822242415100_B96","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1136\/jcp.46.4.297","article-title":"Clonality of chronic neutrophilic leukaemia associated with myeloma: analysis using the X-linked probe M 27 \u03b2.","volume":"46","author":"Standen","year":"1993","journal-title":"J Clin Pathol."},{"key":"2019111822242415100_B97","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/sj.leu.2400938","article-title":"Demonstration of clonality in neutrophils using FISH in a case of chronic neutrophilic leukemia.","volume":"12","author":"Froberg","year":"1998","journal-title":"Leukemia."},{"key":"2019111822242415100_B98","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/(SICI)1096-8652(199803)57:3<221::AID-AJH7>3.0.CO;2-X","article-title":"Neoplastic involvement of granulocytic lineage, not granulocytic-monocytic, monocytic or erythrocytic lineage, in a patient with chronic neutrophilic leukemia.","volume":"57","author":"Yanagiasawa","year":"1998","journal-title":"Am J Hematol."},{"key":"2019111822242415100_B99","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/ajcp\/85.3.369","article-title":"Chronic neutrophilic leukemia: description of a new case with karyotypic abnormalities.","volume":"85","author":"Di Donata","year":"1986","journal-title":"Am J Clin Pathol."},{"key":"2019111822242415100_B100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00005792-197501000-00001","article-title":"The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature.","volume":"54","author":"Chusid","year":"1975","journal-title":"Medicine."},{"key":"2019111822242415100_B101","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1182\/blood.V58.5.1021.bloodjournal5851021","article-title":"A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome. II. Clinical manifestations.","volume":"58","author":"Schooley","year":"1981","journal-title":"Blood."},{"key":"2019111822242415100_B102","first-page":"2","article-title":"Eosinophilic leukaemias and the idiopathic hypereosinophilic syndrome.","volume":"95","author":"Bain","year":"1996","journal-title":"Br J Haematol."},{"key":"2019111822242415100_B103","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/00005792-197109000-00001","article-title":"The natural history of agnogenic myeloid metaplasia (AMM) and a critical evaluation of its relationship with the myeloproliferative syndrome.","volume":"50","author":"Ward","year":"1971","journal-title":"Medicine."},{"key":"2019111822242415100_B104","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0950-3536(98)80036-X","article-title":"The histopathology of chronic myeloproliferative diseases.","volume":"11","author":"Georgi","year":"1998","journal-title":"Baillieres Clin Haematol."},{"key":"2019111822242415100_B105","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1038\/sj.leu.2401553","article-title":"Initial (prefibrotic) stages of idiopathic (primary) myelofibrosis (IMF)\u2014a clinicopathological study.","volume":"13","author":"Thiele","year":"1999","journal-title":"Leukemia."},{"key":"2019111822242415100_B106","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/jlb.67.2.135","article-title":"c-Kit and c-kit mutations in mastocytosis and other hematological diseases.","volume":"67","author":"Boissan","year":"2000","journal-title":"J Leukoc Biol."},{"key":"2019111822242415100_B107","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1073\/pnas.96.4.1609","article-title":"Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis.","volume":"96","author":"Longley","year":"1999","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2019111822242415100_B108","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","article-title":"Diagnostic criteria and classification of mastocytosis: a consensus proposal.","volume":"25","author":"Valent","year":"2001","journal-title":"Leuk Res."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/100\/7\/2292\/1253516\/h81902002292.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/100\/7\/2292\/1253516\/h81902002292.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T22:14:25Z","timestamp":1622153665000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/100\/7\/2292\/106107\/The-World-Health-Organization-WHO-classification"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,10,1]]},"references-count":108,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2002,10,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2002-04-1199","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718874800.793499749","asserted-by":"object"}]},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2002,10,1]]}}}